Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

COUCH Medcomms

- PMLiVE

CureVac advances ‘promising’ seasonal flu mRNA vaccine to phase 2 development

The mid-stage study of the candidate is expected to begin in the fourth quarter of 2023

Digital Opinion Leaders: The Role of Influencers in Medical Communications

There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...

IPG Health

- PMLiVE

Moderna and Immatics announce oncology collaboration worth over $1.7bn

The agreement will focus on the development of bispecifics, cell therapies and cancer vaccines

- PMLiVE

AbbVie shares positive results from head-to-head study of Skyrizi in Crohn’s disease

The late-stage study has been evaluating the drug against Johnson & Johnson’s Stelara

- PMLiVE

Takeda announces positive phase 2b results for TAK-279 in psoriatic arthritis

Approximately 10 million people worldwide are affected by the inflammatory disease

- PMLiVE

IO Biotech announces new data supporting its therapeutic cancer vaccine

The vaccine showed promise when used in combination with Merck & Co’s Keytruda

- PMLiVE

NIHR awards £2.3m for AI study to improve radiotherapy for lung cancer

The AI tool is expected to help doctors plan each patient’s radiotherapy treatment

- PMLiVE

Swordfish Advertising promotes Sam Wright to creative director

Wright originally joined the agency in 2019 as senior art director

- PMLiVE

FDA approves Pfizer/BioNTech and Moderna’s updated COVID-19 vaccines

The vaccines have both been adapted to target the currently circulating XBB.1.5 Omicron variant

- PMLiVE

AstraZeneca’s rare disease unit partners with Verge Genomics in deal worth over $840m

Both will identify drug targets for neurodegenerative and neuromuscular diseases

- PMLiVE

ICR study supports use of new radioactive treatment for advanced prostate cancer

Experts are calling for NICE to assess if the treatment should be made available on the NHS

- PMLiVE

MIT researchers design more powerful RNA vaccines for COVID-19

The new type of RNA vaccine was shown to produce a stronger immune response at a lower dose

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links